AI: DeepSeek (deepseek-chat)

Q: {
  "prompt": "Original Transcript:\nDictation: Clinical Interaction – Twin Pregnancy with Obstetric Cholestasis\n Patient Details:\nName: [Fictional Name] Sarah Ahmed\n\n\nAge: 32\n\n\nBMI: 24.7 (weight 68 kg, height 1.66 m)\n\n\nGravida: 2, Para: 1 (previous spontaneous vaginal delivery at term)\n\n\nCurrent Gestation: 32+2 weeks (DCDA twins confirmed on early scan)\n\n\nBooking bloods and anomaly scans: Unremarkable\n\n\nHistory of Presenting Complaint:\n Ms. Ahmed presents with a 10-day history of worsening pruritus, predominantly affecting her palms and soles, with associated sleep disturbance. She denies any new skin rashes or recent medication changes. No history of abdominal pain, dark urine, or pale stools. Fetal movements are reported as normal for both twins. No vaginal bleeding or uterine tightenings.\nRelevant Obstetric History:\nPrevious pregnancy uncomplicated; term vaginal delivery.\n\n\nNo history of intrahepatic cholestasis in prior pregnancy.\n\n\nNo history of preterm labour or hypertensive disorders.\n\n\nRelevant Medical History:\nMild childhood asthma (not on regular treatment).\n\n\nNo known liver or gallbladder disease.\n\n\nMedications & Allergies:\nCurrently taking ferrous fumarate and pregnancy multivitamin.\n\n\nNo known drug allergies.\n\n\nSocial History:\nLives with husband and toddler son.\n\n\nNon-smoker; does not consume alcohol.\n\n\nWorks part-time as a dental nurse; currently on maternity leave.\n\n\nExamination Findings:\nGeneral: Alert and well, no jaundice noted.\n\n\nAbdomen: Uterus consistent with gestational age; fundal height 33 cm.\n\n\nTwins in cephalic/cephalic lie; both heartbeats auscultated and regular.\n\n\nNo uterine tenderness or signs of labour.\n\n\nNo peripheral oedema; BP 118/74 mmHg.\n\n\nNotable Omissions (for testing purposes):\nNo documented baseline bile acid levels from booking bloods.\n\n\nNo record of fetal growth scan within the last 2 weeks.\n\n\nNo documentation of CTG to assess current fetal wellbeing.\n\n\nImpression:\n Twin pregnancy (DCDA) complicated by suspected obstetric cholestasis. Pruritus in the absence of rash raises concern for intrahepatic cholestasis of pregnancy (ICP), particularly given gestation and multifetal pregnancy.\nManagement Plan:\nInvestigations:\n\n\nSerum bile acids and liver function tests (LFTs) urgently.\n\n\nFasting bile acids if initial results are borderline.\n\n\nFull blood count and clotting screen (due to potential risk of coagulopathy).\n\n\nCTG to assess fetal wellbeing.\n\n\nGrowth scan and umbilical artery Dopplers if not done in past 2 weeks.\n\n\nMedical Management:\n\n\nStart ursodeoxycholic acid 500 mg BID while awaiting results.\n\n\nConsider chlorphenamine for symptomatic relief of itching.\n\n\nOngoing Care and Delivery Planning:\n\n\nWeekly bile acids and LFTs.\n\n\nIncrease surveillance: twice-weekly CTGs and weekly growth scans.\n\n\nAim for delivery at 36–37 weeks if bile acids <100 µmol/L.\n\n\nConsider earlier delivery if bile acids ≥100 µmol/L or evidence of fetal compromise.\n\n\nCounseling Provided:\n\n\nDiscussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\n\n\nReassured about ongoing monitoring and early delivery plan.\n\n\nAdvised to monitor fetal movements closely and report any reduction.\n\n\nProvided written information and contact details for triage if symptoms worsen.\n\n\nDictated by: Dr. [Fictional Name] Patel\n Date: [Fictional Date]\n--Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.\n\n\n\nGuideline Analysis:\n### Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\n\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\n\n### Very Important Recommendations\n1. **Different management plan** - Avoid routine use of ursodeoxycholic acid (UDCA) unless for symptomatic relief, as it does not improve perinatal outcomes.  \n   Reason: The guideline explicitly states, \"Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP.\"  \n\n2. **Different management plan** - Reconsider the recommendation for twice-weekly CTGs and weekly growth scans, as these do not predict or prevent stillbirth in ICP.  \n   Reason: The guideline states, \"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP, so monitoring fetal movements is advised.\"  \n\n3. **Improved patient advice** - Counsel the patient about the increased risk of pre-eclampsia and gestational diabetes, and ensure regular monitoring for these conditions.  \n   Reason: The guideline highlights, \"Women with ICP have a higher chance of developing pre-eclampsia or gestational diabetes. They should have regular monitoring for these conditions.\"  \n\n### Somewhat Important Recommendations\n1. **Additional information needed** - Document baseline bile acid levels from booking bloods if available, as this helps establish a reference for comparison.  \n   Reason: The guideline recommends baseline measurements in subsequent pregnancies, which could also apply to initial assessments in high-risk cases like twin pregnancies.  \n\n2. **Different management plan** - Consider discussing severe or atypical cases with a hepatologist, though this case does not currently appear severe.  \n   Reason: The guideline advises, \"Specialist hepatology advice should be sought for severe, very early, or atypical presentations of ICP.\"  \n\n3. **Improved patient advice** - Provide clearer counseling on the rationale for planned early birth (e.g., based on bile acid levels ≥100 µmol/L) and the lack of evidence for CTG/growth scans in preventing stillbirth.  \n   Reason: The guideline emphasizes individualized delivery timing based on bile acid levels and de-emphasizes unnecessary surveillance.  \n\n### Less Important Recommendations\n1. **Additional information needed** - Consider testing for gestational diabetes if risk factors are present, though not routinely recommended.  \n   Reason: The guideline lists this as a future research question rather than a current recommendation.  \n\n2. **Improved patient advice** - Offer information on ICP recurrence in future pregnancies and the need for baseline testing.  \n   Reason: The guideline notes, \"Women with a history of ICP have an increased chance of recurrence in subsequent pregnancies.\"  \n\n### Unimportant Recommendations\n1. **Additional information needed** - Documenting fasting bile acids if initial results are borderline is reasonable but not critical.  \n   Reason: The guideline does not strongly advocate for additional investigations unless clinically indicated.  \n\n2. **Improved patient advice** - Providing written information and contact details is good practice but not explicitly required by the guideline.  \n   Reason: The guideline supports patient education but does not specify the format.  \n\n### Summary of Key Adjustments:\n- **Stop routine UDCA** unless for symptomatic relief.  \n- **Reduce surveillance intensity** (avoid unnecessary CTGs/growth scans).  \n- **Enhance counseling** on pre-eclampsia/gestational diabetes risks and delivery timing rationale.  \n- **Avoid over-investigation** unless symptoms worsen or bile acids are significantly elevated.  \n\nThese changes align the note with the guideline’s emphasis on evidence-based, risk-stratified management.\n\n\n## Summary\n\nAnalyzed against the most relevant guideline successfully.\n\n*Note: Found 51 relevant guidelines total, analyzed against the most relevant one.*\n\n\nGuideline: Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\n\nPlease extract actionable suggestions from this analysis and format them as specified.",
  "system_prompt": "You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \n\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\n\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\n{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"text from transcript that needs changing\",\n      \"suggestedText\": \"proposed replacement text\",\n      \"context\": \"brief explanation of why this change is suggested\",\n      \"category\": \"addition|modification|deletion|formatting\",\n      \"priority\": \"high|medium|low\",\n      \"guidelineReference\": \"specific guideline section or rule\"\n    }\n  ]\n}\n\nCRITICAL FORMATTING REQUIREMENTS:\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\n- Do not wrap the JSON in ```json or ``` blocks\n- Start your response directly with { and end with }\n- Use sequential numeric IDs starting from \"1\"\n- Ensure all JSON is properly formatted and valid\n\nImportant guidelines:\n- Only suggest changes that are explicitly supported by the guideline analysis\n- Make suggestions specific and actionable\n- Ensure original text selections are precise and findable in the transcript\n- Keep context explanations concise but informative\n- Prioritize suggestions based on clinical importance\n- If no specific suggestions can be made, return {\"suggestions\": []}",
  "transcript_length": 3421,
  "analysis_length": 3937,
  "guideline_id": "bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf",
  "guideline_title": "Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management"
}

A: {
  "suggestions": [
    {
      "id": "1",
      "originalText": "Start ursodeoxycholic acid 500 mg BID while awaiting results.",
      "suggestedText": "Consider ursodeoxycholic acid only for symptomatic relief if needed, as it does not improve perinatal outcomes.",
      "context": "Guideline recommends against routine UDCA use for perinatal outcomes in ICP",
      "category": "modification",
      "priority": "high",
      "guidelineReference": "Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP"
    },
    {
      "id": "2",
      "originalText": "Increase surveillance: twice-weekly CTGs and weekly growth scans.",
      "suggestedText": "Monitor fetal movements closely instead of routine CTGs/growth scans as they don't predict stillbirth in ICP",
      "context": "Guideline states these don't predict or prevent stillbirth in ICP",
      "category": "modification",
      "priority": "high",
      "guidelineReference": "Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP"
    },
    {
      "id": "3",
      "originalText": "Counseling Provided: Discussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.",
      "suggestedText": "Counseling Provided: Discussed nature of obstetric cholestasis, increased risk of stillbirth, pre-eclampsia and gestational diabetes in twin pregnancies.",
      "context": "Guideline highlights need to counsel about additional risks",
      "category": "addition",
      "priority": "high",
      "guidelineReference": "Women with ICP have higher chance of developing pre-eclampsia or gestational diabetes"
    },
    {
      "id": "4",
      "originalText": "No documented baseline bile acid levels from booking bloods.",
      "suggestedText": "Document baseline bile acid levels if available from booking bloods for future reference",
      "context": "Baseline measurements helpful for comparison in high-risk cases",
      "category": "addition",
      "priority": "medium",
      "guidelineReference": "Baseline measurements recommended in subsequent pregnancies"
    },
    {
      "id": "5",
      "originalText": "Impression: Twin pregnancy (DCDA) complicated by suspected obstetric cholestasis.",
      "suggestedText": "Impression: Twin pregnancy (DCDA) complicated by suspected obstetric cholestasis. Will consult hepatologist if severe or atypical features develop.",
      "context": "Guideline recommends specialist input for severe cases",
      "category": "addition",
      "priority": "medium",
      "guidelineReference": "Specialist hepatology advice should be sought for severe presentations"
    },
    {
      "id": "6",
      "originalText": "Aim for delivery at 36–37 weeks if bile acids <100 µmol/L.",
      "suggestedText": "Aim for delivery at 36–37 weeks if bile acids <100 µmol/L, explaining this is based on evidence showing increased risk above this threshold.",
      "context": "Guideline emphasizes need for clear rationale about delivery timing",
      "category": "modification",
      "priority": "medium",
      "guidelineReference": "Individualized delivery timing based on bile acid levels"
    },
    {
      "id": "7",
      "originalText": "No record of fetal growth scan within the last 2 weeks.",
      "suggestedText": "No record of fetal growth scan within the last 2 weeks (not routinely required unless clinical concern).",
      "context": "Guideline de-emphasizes routine growth scans in ICP",
      "category": "modification",
      "priority": "low",
      "guidelineReference": "Avoid unnecessary surveillance in ICP"
    }
  ]
}

--- Token Usage Report ---
Prompt tokens: 1829
Completion tokens: 827
Total tokens: 2656
Estimated cost: $0.001328